Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Net Cash Flow (2023 - 2025)

Historic Net Cash Flow for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to -$3.0 million.

  • Artiva Biotherapeutics' Net Cash Flow fell 11368.28% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 25968.05%. This contributed to the annual value of -$13.3 million for FY2024, which is 7292.81% up from last year.
  • Artiva Biotherapeutics' Net Cash Flow amounted to -$3.0 million in Q3 2025, which was down 11368.28% from -$1.9 million recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Net Cash Flow high stood at $21.6 million for Q3 2024, and its period low was -$15.6 million during Q4 2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$5.3 million (2024), whereas its average is -$2.9 million.
  • Examining YoY changes over the last 5 years, Artiva Biotherapeutics' Net Cash Flow showed a top increase of 8433.04% in 2025 and a maximum decrease of 11368.28% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Net Cash Flow stood at -$12.4 million in 2023, then fell by 26.37% to -$15.6 million in 2024, then soared by 81.08% to -$3.0 million in 2025.
  • Its Net Cash Flow was -$3.0 million in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.6 million in Q1 2025.